New combo could supercharge liver cancer radiation
NCT ID NCT07312292
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a short infusion of angiotensin II, given directly into the liver artery, can help radioactive beads reach liver tumors more effectively while sparing healthy tissue. About 15 adults with liver cancer will receive the drug right before standard radioembolization. Researchers will compare scans to see if the drug improves targeting and check for side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER (LOCALLY ADVANCED OR METASTATIC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Medical Center Utrecht
RECRUITINGUtrecht, Utrecht, 3584 CX, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise as medicine: tailored workouts may rebuild strength after cancer
- Can a heart drug help doctors see liver cancer better?
- Smart nursing cuts kidney damage risk in liver cancer patients
- Can eating only during an 8-10 hour window help liver cancer patients?
- New shot SH009 targets tough cancers in early trial
- New scan could help spare healthy liver during cancer radiation